Fosphenytoin vs Oxcarbazepine (Trileptal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Fosphenytoin
Marketed by Pfizer
NCT01960075 · Phase 3 · completed
This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.
No aligned efficacy figure on record for this race.
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.
Reported efficacy
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)
Result source: NCT00050934
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fosphenytoin | Oxcarbazepine (Trileptal) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00908453 | —Not posted · NCT00050934 |
| 50% responder rate | —Not posted · NCT00908453 | —Not posted · NCT00050934 |
| Seizure freedom | —Not posted · NCT00908453 | —Not posted · NCT00050934 |
Seizure frequency, % change
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
50% responder rate
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
Seizure freedom
- Fosphenytoin
- —Not posted · NCT00908453
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fosphenytoin: 3 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fosphenytoin | Oxcarbazepine (Trileptal) |
|---|---|---|
| Dropout rate | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 14.6%a NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result—400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 12.5%a NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy — NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence | 2.1%a NCT00975715 · Phase 2/3 · combination show 5 more results0%Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination 0%Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence 0%450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence 0% NCT01678976 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence show 1 more result400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence | a somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · combination show 5 more resultssomnolence 75% dizziness 56.3% headache 50% NCT03695094 · Phase 1 · registry result, not featured evidence · combination somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy headache 100% dizziness 85.7% back pain 71.4% NCT00900237 · Phase 1 · registry result, not featured evidence 450 mg Bid dizziness 54.5% somnolence 54.5% frontal headache 18.2% NCT01679002 · Phase 1 · registry result, not featured evidence dizziness 23.1% headache 23.1% nodule subcutaneous 15.4% NCT01678976 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fosphenytoin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Oxcarbazepine (Trileptal)'s landscape